ClinicalTrials.gov
public full text
Public Domain
A Study of GQ1005 in Subjects With HER2-Expressing Advanced Solid Tumors
This is an open-label, phase I study to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of GQ1005 and preliminary anti-tumor efficacy in HER2 expressing or mutated advanced malignant solid tumor subjects.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Clinical Trial of BT02 in Patients With Advanced Solid Tumors#832384
- A Study of SHR-4602 in Subjects With Advanced Malignant Solid Tumors#862657
- A First-in-Human Study of CDK-002 (exoSTING) in Subjects With Advanced/Metastatic, Recurrent, Injectable Solid Tumors#1151326
- Safety of GQ1001 in Adult Patients With HER2-Positive Advanced Solid Tumors#969393
- Phase 1 Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-201#1151351
Record · ID 1127638
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive